Imagion Biosystems Limited has lodged Appendix 4G “Key to Disclosures, Corporate Governance Council Principles and Recommendations” with the Australian Securities Exchange. Read Appendix 4G and Corporate Governance Statement.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)